T0	Outcomes 1861 1892	vaccine-related serious adverse
T1	Outcomes 1915 1940	We recorded local adverse
T2	Outcomes 2095 2109	placebo group.
T3	Outcomes 2110 2117	Fatigue
T4	Outcomes 2410 2422	respectively
T5	Outcomes 2591 2605	placebo group.
T6	Outcomes 2606 2680	Geometric mean concentrations of IgG antibodies against Ebola glycoprotein
T7	Outcomes 2907 2938	(86路5-99路5), and 5% (0路1-24路9).
T8	Outcomes 2939 2948	Geometric
T9	Outcomes 3198 3265	participants given low-dose vaccine developed glycoprotein-specific
T10	Outcomes 3341 3350	responses
T11	Outcomes 3352 3366	INTERPRETATION